Pharmaceutical Grade Cinacalcet Intermediate: High Purity COA & Specifications

• Strict quality control ensures industrial purity exceeding 99% for critical synthesis steps.
• Comprehensive COA documentation includes HPLC, GC-MS, and NMR data for regulatory compliance.
• Reliable bulk procurement of key aldehyde intermediates for global API manufacturing.

Cinacalcet is a potent calcimimetic agent functioning as an agonist of the Calcium-sensing Receptor (CaSR). It is clinically essential for managing secondary hyperparathyroidism in patients undergoing dialysis and primary hyperparathyroidism in individuals unsuitable for surgery. The commercial availability of this active pharmaceutical ingredient relies heavily on the consistent supply of high-quality precursors. Among these, the aldehyde derivative serves as a critical building block in the final amination steps. Ensuring the high purity of this precursor is paramount to minimizing downstream impurities such as diastereomers in the final API.

As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. specializes in the production of complex organic intermediates required for modern pharmaceutical synthesis. Our facility adheres to rigorous quality management systems to support the global demand for calcimimetic therapies. This technical overview details the analytical protocols, impurity specifications, and documentation standards required for procuring pharmaceutical-grade intermediates.

Optimized Synthesis Route and Chemical Stability

The production of Cinacalcet involves a multi-step organic sequence where the integrity of the starting materials dictates the overall yield and quality of the final drug substance. The key intermediate, often referred to as 3-[3-(Trifluormethyl)phenyl]propionaldehyde, undergoes reductive amination with a chiral amine to form the final active structure. Maintaining stability during this synthesis route is critical, as aldehydes are susceptible to oxidation and polymerization if not stored correctly.

Industrial scale manufacturing requires intermediates that meet specific physical and chemical standards to ensure reaction consistency. When sourcing 3-[3-(Trifluoromethyl)phenyl]propanal, buyers should verify that the supplier provides data on moisture content and peroxide levels, as these factors can significantly impact catalyst performance in subsequent steps. Our production processes are designed to maximize yield while minimizing side reactions that lead to difficult-to-remove byproducts.

For detailed specifications and availability of this critical precursor, manufacturers can review the technical dossier for 3-[3-(Trifluoromethyl)phenyl]propanal. Access to consistent batches with verified purity profiles allows API manufacturers to streamline their regulatory filings and reduce production risks.

HPLC and GC-MS Testing Protocols

Quality assurance for pharmaceutical intermediates relies on robust analytical methods. To guarantee industrial purity, every batch undergoes comprehensive testing using High-Performance Liquid Chromatography (HPLC) and Gas Chromatography-Mass Spectrometry (GC-MS). These techniques are essential for quantifying the main component and detecting trace organic volatiles.

The HPLC method typically utilizes a reverse-phase column with UV detection to separate the target aldehyde from related substances. Acceptance criteria usually require the main peak area to constitute not less than 99.0% of the total area. Additionally, GC-MS is employed to identify residual solvents such as dichloromethane, toluene, or hexanes used during the purification process. Compliance with ICH Q3C guidelines for residual solvents is mandatory for any Cinacalcet intermediate intended for human therapeutic use.

Advanced characterization also includes spectroscopic analysis. A complete data package should encompass 1H NMR and 13C NMR spectra to confirm chemical structure and connectivity. Infrared (IR) spectroscopy provides further verification of functional groups, ensuring the carbonyl stretch and trifluoromethyl signatures match the reference standard. This multi-method approach ensures that the material is chemically identical to the required specification.

Impurity Profile Specifications

Controlling impurities is a critical aspect of API manufacturing. During the synthesis, storage, or degradation of Cinacalcet, various impurities may develop, resulting from starting materials, reagents, or undesired side reactions. For the aldehyde intermediate, specific attention is paid to oxidation products (carboxylic acids) and reduction products (alcohols).

Furthermore, the final API is prone to forming diastereomers due to the chiral center introduced during amination. While the intermediate itself may not be chiral, its purity influences the diastereomeric ratio in the final step. Leading manufacturers generate impurity standards, such as diastereomer hydrochloride salts, to validate analytical methods. Regular monitoring of impurity levels is performed during the production and release of commercial batches to ensure compliance with set specifications.

Impurity profiles may vary among different brands of Cinacalcet due to variations in manufacturing processes. Therefore, sourcing intermediates with a known and controlled impurity profile allows the API manufacturer to predict and manage the final drug substance quality more effectively. Acceptable limits for individual unknown impurities are typically set at 0.10%, with total impurities not exceeding 0.5%.

Certificate of Analysis Breakdown

A valid Certificate of Analysis (COA) is the primary document verifying the quality of the shipped material. For pharmaceutical-grade intermediates, the COA must be generated from an analytical facility compliant with cGMP standards. It serves as a legal declaration that the product meets all agreed-upon specifications.

A comprehensive COA for this intermediate includes the following key sections:

• Product Identification: Includes chemical name, CAS number (21172-41-8), and batch number.
• Physical Properties: Appearance, color, and odor description.
• Assay: Quantitative result of the main component via HPLC or GC.
• Impurities: List of known and unknown impurities with respective percentages.
• Residual Solvents: Compliance data for Class 1, 2, and 3 solvents.
• Storage Conditions: Specific instructions, typically controlled room temperature between 2-8 °C or as indicated.

On request, suppliers should provide additional data like 13C-DEPT and CHN analysis to support regulatory submissions. NINGBO INNO PHARMCHEM CO.,LTD. ensures that every delivery is accompanied by a complete characterization report. This transparency facilitates smoother audits and faster regulatory approvals for downstream customers.

Conclusion

The reliability of the Cinacalcet supply chain depends on the quality of its precursors. By prioritizing high purity intermediates with full analytical documentation, pharmaceutical companies can ensure the safety and efficacy of the final medication. With a focus on custom synthesis and stable supply chains, we remain committed to supporting the global healthcare industry with superior chemical solutions.